Trisaluslifesci
Westminster, US · Founded 2020 · 135 employees on LinkedIn · 2 known investors
TriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Founders & leadership
SM
Sean MurphyinExecutive
JE
Jennifer E. StevensinChief Regulatory, Quality and Therapeutic Development Officer
RB
Richard B. MarshakinChief Commercial Officer
MS
Mary SzelaExecutive
JD
Jodi DevlininChief, Clinical Strategy and Operations2023–2026
RH
Robert H. WeissChief Administrative Officer and Secretary
CC
Christopher C. DeweyChief Executive Officer
DL
David L. TreadwellNamed on SEC filing
MR
Martin RocheNamed on SEC filing
MA
Manuel AgueroNamed on SEC filing
TT
Thierry ThaureNamed on SEC filing
Board
DM
David MatlinBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$40.9M disclosed across 3 rounds · 2023–2025
▶$22MraisedMay 2025 · 24 investors · BiotechnologyRule 506(b)
▶$22MraisedMay 2025 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mats WahlstromDirector
- Jennifer StevensExecutive Officer
- David J. MatlinDirector
- Jodi DevlinExecutive Officer
- Arjun DesaiDirector
- Sean MurphyDirector
- Richard MarshakExecutive Officer
- Gary GordonDirector
- James YoungExecutive Officer
- Mary SzelaExecutive Officer, Director
- Andrew von EschenbachDirector
- Kerry HicksDirector
- Brian CoxExecutive Officer
- William F. ValleDirector
- Offering amount
- $22M
- Amount sold
- $22M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1000KraisedDec 2024 · 6 investors · BiotechnologyRule 506(b)
▶$1000KraisedDec 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean MurphyExecutive Officer, Director
- Kerry HicksDirector
- Jennifer E. StevensExecutive Officer
- Mats WahlstromDirector
- Richard B. MarshakExecutive Officer
- Liselotte HyveledDirector
- David MatlinDirector
- Mary SzelaExecutive Officer, Director
- Jodi DevlinExecutive Officer
- Arjun DesaiDirector
- George Kelly MartinDirector
- Andrew von EschenbachDirector
- Bryan F. CoxExecutive Officer
- Offering amount
- $1000K
- Amount sold
- $1000K
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$17.9MraisedJun 2023 · 17 investors · Other Health CareRule 506(b)
▶$17.9MraisedJun 2023 · 17 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert H. WeissExecutive Officer
- David L. TreadwellDirector
- Karim KartiDirector
- Martin RocheDirector
- Christopher C. DeweyExecutive Officer, Director
- Manuel AgueroDirector
- Thierry ThaureDirector
- David J. MatlinExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $17.9M
- Sales commissions
- $3.3M
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Trisaluslifesci do?
- TriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
- Who are Trisaluslifesci's investors?
- Trisaluslifesci's investors include OrbiMed, Tullis Health Investors.
- How much funding has Trisaluslifesci raised?
- Trisaluslifesci has disclosed $40.9M raised across 3 rounds.
- Where is Trisaluslifesci headquartered?
- Trisaluslifesci is headquartered in Westminster, US.